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Background: Knee osteoarthritis (OA) is a complex disease involving both biomechanical and metabolic factors
that alter the tissue homeostasis of articular cartilage and subchondral bone. The catabolic activities of extracellular
matrix degradation products, especially fibronectin (FN), have been implicated in mediating cartilage degradation.
Chondrocytes express several members of the integrin family which can serve as receptors for FN including
integrins α5β1, αvβ3, and αvβ5. The purpose of this study was to determine whether polymorphisms in the FN
(FN-1) and integrin genes are markers of susceptibility to, or severity of, knee OA in a Han Chinese population.
Methods: Two independent case–control studies were conducted on 928 patients with knee OA and 693 healthy
controls. Ten single nucleotide polymorphisms (SNPs) of FN-1 and the integrin αV gene (ITGAV) were detected
using the ABI 7500 real-time PCR system.
Results: The AT heterozygote in FN-1 (rs940739A/T) was found to be significantly associated with knee OA
(adjusted OR = 1.44; 95% CI = 1.16–1.80) in both stages of the study. FN-1 rs6725958C/A and ITGAV rs10174098A/G
SNPs were only associated with knee OA when both study groups were combined. Stratifying the participants by
Kellgren-Lawrence (KL) score identified significant differences in the FN-1 rs6725958C/A and rs940739 A/T genotypes
between patients with grade 4 OA and controls. Haplotype analyses revealed that TGA and TAA were associated
with a higher risk of OA, and that TAG conferred a lower risk of knee OA in the combined population.
Conclusions: Our study suggests that the FN-1 rs940739A/T polymorphism may be an important risk factor of
genetic susceptibility to knee OA in the Han Chinese population.
Keywords: Knee osteoarthritis, Fibronectin gene, Integrin αV gene, Single nucleotide polymorphismBackground
Osteoarthritis (OA) is a degenerative joint disease that
progressively causes loss of joint function and is a leading
cause of disability and impaired quality of life among the
elderly in developed countries. It is characterized by
degeneration and the progressive loss of articular cartilage
with pathological changes in bone, synovium, and other
soft tissues of affected joints [1]. A number of factors, such* Correspondence: chianherlee@yahoo.com.tw
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excessive mechanical loading, are recognized to contribute
to OA onset and progression [2]. As such, OA is a complex
disease involving both biomechanical and metabolic factors
that alter the tissue homeostasis of articular cartilage and
subchondral bone [3].
The catabolic activities of matrix degradation products,
including fibronectin fragments (FN-fs), have been
implicated in mediating cartilage degradation [4,5]. At
least some of these fragments appear to act via an
integrin-dependent mechanism [6]. Chondrocytes expressd. This is an Open Access article distributed under the terms of the Creative
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FN receptors, including α5β1, αvβ3, and αvβ5 [7,8].
FN is encoded by FN-1, which is located on chromosome
2q34-36, is over 75 kb in length and is composed of
50 exons. FN is a multifunctional glycoprotein that is
involved in a wide range of biological processes such
as cell migration, wound healing, angiogenesis, and
differentiation. FN exists in two major forms. The soluble
form is found in the plasma, while the insoluble form is
present in tissues, including at low levels in the extracellular
matrix (ECM) of normal cartilage [9]. Alternative splicing
of two type III exons, known as Extra Domains A and B,
and a variable region result in the production of up to 20
different FN variants [10]. Growing evidence suggests
that these isoforms affect the function of FN and FN-fs,
including cartilage breakdown in OA [11].
Integrins are cell surface receptors composed of α and
β chains. The integrin family consists of at least 24
different heterodimers that are involved in cell–cell and
cell–ECM adhesion [12]. Integrin αV (ITGAV) is one of
the more promiscuous alpha integrins associating with
five different beta subunits including β1, β3, β5, β6, and
β8 [13]. Expression of ITGAV appears to be upregulated
in osteoarthritic chondrocytes [14].
Single nucleotide polymorphisms (SNPs) represent
variations in the genome between individuals. Several
studies have demonstrated that a number of these
polymorphisms are associated with OA and may contribute
to the genetic risk of developing the disease [15-17].
Because FN-1 and ITGAV polymorphisms may influence
gene expression or modify the biological activities of the
functional protein, we set out to test the hypothesis
that such polymorphisms influence susceptibility and
the severity of knee OA.
Methods
A total of 928 patients with knee OA and 693 healthy
individuals were recruited for two independent studies
carried out between July 2008 and December 2009
(the first study conducted in Miaoli, which is located
in a largely rural area of China) and between March
2010 and June 2011 (the second study conducted in
the centrally located Chinese city of Taipei). The first
study recruited and genotyped 403 knee OA patients
(65.4% female) and 314 controls (53.8% female) to identify
knee OA-associated SNPs and haplotypes. The second
study recruited and genotyped 525 knee OA patients
(65.6% female) and 379 healthy controls (58.6% female).
Disease severity in the knee OA populations, who were
attending an orthopedic hospital, was assessed by
Kellgren-Lawrence (KL) grading. All patients had a KL
score ≥ 2. Other etiologies of knee joint disease such as
inflammatory arthritis, post-traumatic or post-septic
arthritis, and skeletal or developmental dysplasia wereexcluded from the study. Healthy control subjects had
no signs or symptoms of joint disease (pain, swelling,
tenderness, or restriction of movement) and standard
x-rays of the knee joints confirmed an absence of OA.
This study was reviewed and approved by the institutional
ethical committee of Taipei Medical University Hospital
and Tri-Service General Hospital (CRC-01-10-03 and
TSGH-100-05-023). All clinical and biological samples
were collected and DNA was genotyped following
approval by this committee. Written informed consent
was obtained from all participants after the study had
been fully explained to them.
Selection and genotyping of polymorphisms
We selected FN-1 and ITGAV as candidate genes based on
the published literature [18,19]. SNP genotype information
was downloaded from the HapMap database (http://
hapmap.ncbi.nlm.nih.gov/) and The National Center for
Biotechnology Information dbSNP database (http://www.
ncbi.nlm.nih.gov/snp) to select the most representative
SNPs by capturing the majority of genetic variation. Using
the tagger program implemented in Haploview 4.0, tag
SNPs across FN-1 and ITGAV were selected on the basis
of linkage disequilibrium patterns observed in the Han
Chinese samples genotyped as part of the International
HapMap Project. Only SNPs with a minor allele frequency
greater than 5% in HapMap were considered. Six SNPs
(rs10202709, rs6725958, rs940739, rs2304573, rs11651,
and rs3796123) in FN-1 and four SNPs (rs3911238,
rs10174098, rs3738929, and rs1448427) in ITGAV were
included to capture as much variation as possible. These
10 tag SNPs captured all alleles with an r2 of at least 0.8.
Genomic DNA was extracted from the peripheral blood
of patients and controls using the QIAamp DNA Blood
Mini Kit (QIAGEN Inc., Hilden, Germany) according
to the manufacturer’s instructions. Genotyping was
performed using the TaqMan® SNP Genotyping Assay
(Applied Biosystems, Foster City, CA, USA) with the
following cycling conditions: 95°C for 10 min, followed by
40 cycles of 95°C for 15 s and 60°C for 1 min, with a 1 min
extension at 25°C following the last cycle. Genotyping was
performed by laboratory personnel blinded to case status
and 10% of the samples were randomly selected for
repeated testing to validate genotyping procedures. Two
authors independently reviewed the genotyping results,
data entry, and statistical analyses.
Statistical analysis
Statistical analysis was performed using SPSS for Windows
version 18.0 software (SPSS, Chicago, IL, USA), and results
were considered statistically significant where the
two-tailed p-value was less than 0.05. SNP deviations from
the Hardy-Weinberg equilibrium (HWE) in control
samples were assessed using the standard chi-squared (χ2)
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and control subjects were compared using χ2 statistics or
Fisher’s exact test as appropriate. The demographics were
evaluated by the Student’s t-test or Mann–Whitney U
test for continuous variables and expressed as means ±
standard deviation (SD). Logistic regression was used to
estimate crude and adjusted age, gender, and body mass
index (BMI) odd ratios (ORs) and 95% confidence intervals
(CIs) as a measure of association with the risk of OA.
Linkage disequilibrium and haplotype analyses were
performed using Haploview software (http://www.broad.
mit.edu/mpg/haploview/) [20]. Because the frequency
distributions of demographic characteristics and genotypic
and allelic distributions of the 10 SNPs were similar
between the two study cohorts, all data were pooled to
analyze the association between SNPs and knee OA. In
the absence of interstudy heterogeneity within samples,
we also constructed a Mantel-Haenszel meta-analysis of
sample data to assess the overall evidence of association.
The Mantel-Haenszel χ2 test and estimate of the OR were
computed with or without the inclusion of covariates
using R, version 3.0.2, with the “metafor” and “meta”
packages.
The assumption of heterogeneity for each analysis
was tested using the DerSimonian-Laird method. The
level of significance was determined by Bonferroni’s
method for correcting multiple testing errors. For the
10 selected SNPs, a p-value < 0.005 (0.05 divided by 10)
was considered statistically significant. In this study,
power estimation was performed using CaTS (http://www.
sph.umich.edu/csg/abecasis/CaTS/) and is summarized in
Additional file 1: Table S1.
Results
Characteristics of study subjects
The frequency distributions of demographic characteristics
between the 928 knee OA cases and 693 healthy controls
in the two independent studies are shown in Table 1. TheTable 1 Characteristics of OA cases and healthy controls
Variables Study 1 Study 2
Case (%) Control (%) Case (%)
Number 403 314 525
Age (mean ± SD) 72.54 ± 8.13 69.34 ± 9.80 72.18 ± 8.12
Gender (% Female) 65.4% 53.8% 65.6%
BMI (mean ± SD) 25.28 ± 3.13 24.95 ± 9.88 25.08 ± 3.16
K-L grading (%)
Grade 0 0 162 (51.60) 0
Grade 1 0 152 (48.40) 0
Grade 2 146 (36.23) 0 205 (39.05)
Grade 3 73 (18.11) 0 74 (14.10)
Grade 4 184 (45.66) 0 246 (46.85)average age of knee OA cases was significantly higher than
the control population. The proportion of females in the
knee OA cases (65.5%) was significantly higher than in the
healthy controls (56.4%). BMI was also slightly higher in
the knee OA cases.
Association analyses of FN-1 polymorphisms with
susceptibility to OA
Table 2 shows the genotype distributions and allele
frequencies of FN-1 polymorphisms in knee OA and
control subjects from both studies. The genotype
frequencies of all six FN-1 SNPs were in HWE (p > 0.05).
In study 1, the genotype distribution of FN-1 rs940739A/T
was significantly different between knee OA patients and
healthy controls (p < 0.05). When the FN-1 rs940739AA
genotype was used as the reference group, the rs940739AT
genotype appeared to be associated with a higher risk for
knee OA (adjusted OR = 1.44, 95% CI = 1.03–2.01). To
determine whether the results could be replicated, we
genotyped the six SNPs in the second study population. In
this study group, rs940739AT also differed significantly in
genotype distribution between the knee OA cases and
healthy controls (adjusted OR = 1.48, 95% CI = 1.10–1.99).
The other FN-1 SNPs (rs10202709G/A, rs6725958C/A,
rs2304573G/A, rs11651A/G, and rs3796123T/A) demon-
strated no significant genotypic or allelic association
between OA cases and healthy controls in either of the
two study groups (Table 2).
Association analyses for FN-1 polymorphisms in the
combined studies
When data from the two independent studies were
combined, the association of the rs940739A/T polymorph-
ism with knee OA was maintained (adjusted OR= 1.44,
95% CI = 1.16–1.80, p = 0.001). Additionally, the minor
allele of FN-1 rs6725958C/A appeared to be associated with
a significantly higher risk of knee OA (adjusted OR= 1.17,
95% CI = 1.01–1.80, p = 0.033) (Table 3). After correctingStudy 1 + Study 2
Control (%) Case (%) Control (%) p
379 928 693
69.87 ± 9.96 72.34 ± 8.13 69.63 ± 9.88 < 0.001
58.6% 65.5% 56.4% < 0.001
24.26 ± 3.79 25.17 ± 3.15 24.57 ± 7.22 0.04
189 (49.87) 0 351 (50.65)
190 (50.13) 0 342 (49.35)
0 351 (37.82) 0
0 147 (15.84) 0
0 430 (46.34) 0
Table 2 Genotype distributions of FN-1 polymorphisms and their association with OA risk
SNP Study 1 Study 2
Case Control Adjusted OR (95% CI) # Case Control Adjusted OR (95% CI) #
rs10202709 GG 376 300 1 488 351 1
GA 26 13 1.64 (0.81-3.33) 35 27 0.88 (0.52-1.52)
AA 1 1 1.00 (0.06-16.72) 2 1 1.24 (0.11-14.25)
G 0.96 0.98 1 0.96 0.96 1
A 0.04 0.02 1.54 (0.80-2.97) 0.04 0.04 0.94 (0.55-1.52)
rs6725958 CC 113 102 1 120 111 1
CA 200 158 1.08 (0.76-1.54) 289 197 1.25 (0.90-1.72)
AA 90 54 1.44 (0.92-2.25) 116 71 1.37 (0.92-2.05)
C 0.53 0.58 1 0.50 0.55 1
A 0.47 0.42 1.18 (0.95-1.47) 0.50 0.45 1.16 (0.96-1.41)
rs940739 AA 240 208 1 310 260 1
AT 146 94 1.44 (1.03-2.01)* 191 104 1.48 (1.10-1.99)*
TT 17 12 1.07 (0.49-2.36) 24 15 1.15 (0.58-2.28)
A 0.78 0.81 1 0.77 0.82 1
T 0.22 0.19 1.26 (0.96-1.65) 0.23 0.18 1.30 (1.02-1.65)*
rs2304573 GG 227 173 1 302 212 1
GA 146 119 0.95 (0.68-1.31) 189 137 0.99 (0.74-1.33)
AA 30 22 1.15 (0.63-2.10) 34 30 0.80 (0.47-1.36)
G 0.74 0.74 1 0.75 0.74 1
A 0.26 0.26 1.02 (0.79-1.30) 0.25 0.26 0.93 (0.75-1.17)
rs11651 AA 190 138 1 251 167 1
AG 170 130 0.93 (0.67-1.29) 213 164 0.89 (0.66-1.19)
GG 43 46 0.71 (0.44-1.16) 61 48 0.85 (0.55-1.31)
A 0.68 0.65 1 0.68 0.66 1
G 0.32 0.35 0.86 (0.68-1.08) 0.32 0.34 0.91 (0.74-1.11)
rs3796123 TT 338 259 1 430 318 1
TA 61 52 0.83 (0.54-1.27) 87 60 1.07 (0.74-1.54)
AA 4 3 1.02 (0.22-4.68) 8 1 6.17 (0.73-52.51)
T 0.91 0.91 1 0.90 0.92 1
A 0.09 0.09 0.87 (0.59-1.27) 0.10 0.08 1.21 (0.86-1.70)
*p < 0.05; #Data have been adjusted by gender, age and BMI.
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had a higher risk for OA, but the minor allele of FN-1
rs6725958C/A was not significant.
Association analyses for ITGAV polymorphisms in the
combined studies
Genotypic and allelic distributions of the four ITGAV
SNPs and their associations with knee OA risk are
shown in Table 4. No deviation from the HWE was
observed in the controls (p > 0.05). There was no significant
genotypic or allelic association identified between the knee
OA cases and healthy controls with the four ITGAV
SNPs in both study cohorts. However, when data
from the two independent studies were combined,rs10174098A/G was associated with a lower risk of knee
OA (adjusted OR = 0.77, 95% CI = 0.62–0.96, p = 0.020).
In males, significant associations were observed between
ITGAV rs3738919C/A and OA (Additional file 1: Table S4),
but no associations were found between OA and FN-1
polymorphisms among males (Additional file 1: Table S2).
In females, genotypic and allelic frequencies of FN-1
rs6725958C/A and rs940739A/T and ITGAV rs10174098A/
G polymorphisms differed significantly between knee OA
cases and healthy controls (Additional file 1: Tables S3
and S4). Additionally, the dominant mode of FN-1
rs640739 also appeared to be associated with a signifi-
cantly higher risk of knee OA (adjusted OR = 1.41, 95%
CI = 1.14–1.74, p = 0.002) (Additional file 1: Table S5).
Table 3 Association analyses for FN-1 SNPs with OA in the combined analyses of both study groups
SNP Case Control Simply pooled OR (95% CI)# p ORMeta (95% CI)
# I2
rs10202709 GG 864 651 1 1
GA 61 40 1.13 (0.74-1.72) 0.583 1.15 (0.63-2.10) 47.99
AA 3 2 1.15 (0.19-711) 0.881 1.13 (0.18-7.09) 0
G 0.96 0.97 1 1
A 0.04 0.03 1.24 (0.76-1.67) 0.565 1.16 (0.72-1.87) 23.50
rs6725958 CC 233 213 1 1
CA 489 355 1.17 (0.92-1.48) 0.201 1.08 (0.76-1.53) 0
AA 206 125 1.39 (1.03-1.88) 0.030 1.40 (1.04-1.89) 0
C 0.52 0.56 1 1
A 0.48 0.44 1.17 (1.01-1.35) 0.033 1.17 (1.01-1.35) 0
rs940739 AA 550 468 1 1
AT 337 198 1.44 (1.16-1.80) 0.001& 1.46 (1.17-1.83) 0
TT 41 27 1.14 (0.68-1.91) 0.624 1.11 (0.67-1.86) 0
A 0.77 0.82 1 1
T 0.23 0.18 1.28 (1.07-1.53) 0.008 1.28 (1.07-1.54) 0
rs2304573 GG 529 385 1 1
GA 335 256 0.97 (0.78-1.20) 0.754 0.97 (0.78-1.21) 0
AA 64 52 0.93 (0.62-1.38) 0.701 0.94 (0.63-1.40) 0
G 0.75 0.74 1 1
A 0.25 0.26 0.96 (0.82-1.13) 0.647 0.97 (0.82-1.14) 0
rs11651 AA 441 305 1 1
AG 383 294 0.90 (0.73-1.12) 0.359 0.91 (0.73-1.13) 0
GG 104 94 0.78 (0.57-1.08) 0.138 0.78 (0.57-1.08) 0
A 0.68 0.65 1 1
G 0.32 0.35 0.88 (0.76-1.03) 0.112 0.89 (0.76-1.04) 0
rs3796123 TT 768 577 1 1
TA 148 112 0.95 (0.72-1.25) 0.691 0.96 (0.73-1.27) 0
AA 12 4 2.14 (0.67-6.87) 0.202 2.14 (0.38-12.14) 44.49
T 0.91 0.91 1 1
A 0.09 0.09 1.03 (0.80-1.33) 0.818 1.04 (0.75-1.44) 36.03
#Data have been adjusted by gender, age and BMI; &p-values were based upon Bonferroni’s method.
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showed no significance (Additional file 1: Table S6). After
correcting for multiple comparisons, no SNPs appeared to
be associated with OA. We further analyzed interactions
between FN-1 rs940739A/T and obesity, but observed no
significant interaction between the two (p for interaction =
0.15 for the interaction term, Additional file 1: Table S7).
Stratification analysis according to disease severity
Stratifying the patients by KL score identified significant
differences in FN-1 rs6725958C/A alleles and genotypes
between patients with both grade 3 and 4 knee OA and
controls (AA/CC, adjusted OR = 2.11, 95% CI = 1.45–3.06;
adjusted OR = 0.54, 95% CI = 0.36–0.82; CA/CC, adjusted
OR = 1.58, 95% CI = 1.16–2.16). FN-1 rs940739A/T wasalso associated with grade 4 knee OA (AT/AA, adjusted
OR = 2.07, 95% CI = 1.59–2.69) (Table 5).
Haplotype analysis of FN-1
Linkage disequilibrium analysis confirmed disequilibrium
between SNPs rs2304573 and rs11651 (r2 = 0.73; data not
shown). The haplotype analysis of FN-1 polymorphisms in
knee OA cases and control subjects is shown in Table 6.
The frequency of haplotype AAG was 6.6% in knee OA
patients compared with 10.1% in controls (OR = 0.63,
95% CI = 0.49–0.81, p < 0.001). By contrast, haplotypes
TGA and TAA were more common in knee OA patients
(4.7% and 2.2%, respectively) than controls (2.4% and 1.0%,
respectively) (OR = 2.03 and 2.12, 95% CI = 1.35–3.06 and
1.16–3.89, p < 0.001 and = 0.013, respectively).
Table 4 Genotype distributions of ITGAV polymorphisms and their association with OA risk
SNP Study 1 Study 2 Study 1 + Study 2
Case Control OR (95% CI)# Case Control OR (95% CI)# OR (95% CI)#$ ORMeta I
2
rs3911238 GG 294 216 1 381 266 1 1 1
GC 99 89 0.84 (0.59-1.82) 129 101 0.86 (0.63-1.18) 0.84 (0.67-1.06) 0.85 (0.67-1.08) 0
CC 10 9 0.92 (0.36-2.40) 15 12 0.92 (0.42-2.03) 0.93 (0.51-1.72) 0.92 (0.50-1.68) 0
G 0.85 0.83 1 0.85 0.84 1 1 1
C 0.15 0.17 0.87 (0.65-1.17) 0.15 0.16 0.89 (0.69-1.16) 0.88 (0.73-1.07) 0.88 (0.73-1.07) 0
rs10174098 AA 285 209 1 351 240 1 1 1
AG 104 96 0.74 (0.52-1.04) 154 129 0.77 (0.57-1.03) 0.77 (0.62-0.96) 0.76 (0.60-0.95) 0
GG 14 9 1.27 (0.53-3.05) 20 10 1.19 (0.53-2.64) 1.22 (0.68-2.20) 1.23 (0.68-2.22) 0
A 0.84 0.82 1 0.82 0.80 1 1 1
G 0.16 0.18 0.86 (0.65-1.14) 0.18 0.20 0.87 (0.68-1.11) 0.88 (0.73-1.05) 0.87 (0.72-1.04) 0
rs3738919 CC 366 273 1 468 344 1 1 1
CA 35 37 0.66 (0.39-1.09) 54 44 0.87 (0.56-1.34) 0.77 (0.55-1.06) 0.78 (0.55-1.09) 0
AA 2 4 0.29 (0.05-1.70) 3 1 2.18 (0.22-21.58) 0.70 (0.19-2.50) 0.69 (0.10-4.90) 46.58
C 0.95 0.93 1 0.94 0.94 1 1 1
A 0.05 0.07 0.60 (0.38-0.95) 0.06 0.06 0.93 (0.62-1.40) 0.77 (0.57-1.04) 0.76 (0.49-1.16) 49.44
rs1448427 AA 267 196 1 325 234 1 1 1
AG 123 108 0.90 (0.37-2.18) 179 129 1.00 (0.49-2.03) 0.91 (0.74-1.13) 0.96 (0.55-1.67) 0
GG 13 10 0.79 (0.57-1.10) 21 16 1.00 (0.75-1.34) 0.96 (0.55-1.66) 0.90 (0.72-1.13) 11.32
A 0.82 0.80 1 0.79 0.79 1 1 1
G 0.18 0.20 0.85 (0.65-1.12) 0.21 0.21 1.00 (0.79-1.27) 0.94 (0.79-1.12) 0.93 (0.78-1.11) 0
#Data have been adjusted by gender, age and BMI; $Simply pooled OR.
Table 5 Association of FN-1 rs6725958 and rs940739









CC 233 AA/CC 2 1.10 (0.74-1.65) 0.628
CA 489 AA/CC 3 0.81 (0.49-1.35) 0.418
AA 206 AA/CC 4 2.11 (1.45-3.06) < 0.001
CA/CC 2 1.14 (0.83-1.55) 0.427
CA/CC 3 0.54 (0.36-0.82) 0.003
CA/CC 4 1.58 (1.16-2.16) 0.004
rs940739
AA 550 TT/AA 2 1.12 (0.59-2.14) 0.729
AT 337 TT/AA 3 1.37 (0.59-3.18) 0.465
TT 41 TT/AA 4 1.15 (0.59-2.24) 0.668
TA/AA 2 0.96 (0.71-1.30) 0.801
TA/AA 3 1.22 (0.82-1.18) 0.339
TA/AA 4 2.07 (1.59-2.69) < 0.001
$Grade 0, 1 as a reference category; OA cases = study 1 + study 2; #Data have
been adjusted by gender, age and BMI.
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After conducting two independent studies involving the
genotyping and evaluation of disease severity of 928
knee OA patients and 693 healthy controls from a Han
Chinese population, we have identified an association
between the FN-1 rs940739A/T SNP and OA. When data
from both studies were combined, we also identified an
association between the ITGAV rs10174098A/G SNP and
knee OA.
Several recent studies have identified FN-1 mutations
and polymorphisms that affect host susceptibility to a
variety of diseases including calcium oxalate stone
disease [21], schizophrenia [22], lung cancer [23], and
fibrosing alveolitis in systemic sclerosis [24]. However,
no previous studies have reported on an association
between FN-1 polymorphisms and knee OA. The current
study has, for the first time, revealed that the FN-1
intronic polymorphism rs940739A/T is associated with
knee OA. SNPs in introns are known to influence the
regulation of transcription, splicing, and other aspects of
RNA processing or stability [25,26]. For instance, the
intronic SNPs in FTO [27], COL1A1 [28], and BANK1
[29] affect primary transcript levels while the risk allele of
the intronic SNP in the prothrombin gene may influence
splicing efficiency [30]. However, it is currently unclear
Table 6 Haplotype analysis of the three identified SNPs in FN-1 between OA cases and control subjects in both studies
Haplotype Frequencies p OR (95% CI)
rs940739 rs2304573 rs11651 Case Control
A G A 0.581 0.597 0.386 0.94 (0.82-1.08)
T G G 0.130 0.127 0.771 1.03 (0.84-1.27)
A G G 0.095 0.099 0.729 0.96 (0.76-1.21)
A A G 0.066 0.101 < 0.001 0.63 (0.49-0.81)
T G A 0.047 0.024 < 0.001 2.03 (1.35-3.06)
A A A 0.031 0.022 0.087 1.47 (0.94-2.30)
T G G 0.027 0.021 0.289 1.28 (0.81-2.03)
T A A 0.022 0.010 0.013 2.12 (1.16-3.89)
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knee OA in the current study performs a functional role by
exerting a direct effect on FN-1 expression or whether it is
in linkage disequilibrium with another functional SNP.
The role of FN and FN-fs in the development of knee
OA is well recognized and supported by a number of
studies. FN-fs, the central cell-, NH2-terminal heparin-,
and NH2-terminal gelatin-binding fragments of FN have
been shown to stimulate cartilage chondrolysis by inhibit-
ing anabolic activity while increasing production of matrix
metalloproteinases [31]. Importantly, FN-1 expression
appears to be differentially regulated in monolayer cultured
chondrocytes from OA and normal donors [32].
When we analyzed the association of SNP expression
with the radiological grade of knee OA, a significant
relationship was seen in patients with KL grade 4 knee
OA with genotypes rs6725958C/A and rs940739A/T, indi-
cating that these FN-1 polymorphisms are associated with
advanced knee OA in the current Han Chinese popula-
tion. The reasons for these associations are not clear.
Genetic risk factors can influence the risk of development
and progression of knee OA at various stages during the
course of the disease. Because FN-1 polymorphisms
could contribute to the risk of OA at different phases
or throughout the disease process, further functional
studies on such polymorphisms are required.
Haplotype analysis demonstrated an association between
FN-1 and knee OA. Our data revealed that patients carrying
TGA or TAA haplotypes had a higher risk of developing
knee OA than those without, suggesting that multiple
variants in FN-1 affect the risk. The FN-1 haplotype has
previously been shown to have a significant influence on
whether a fetus is at risk of being small-for-gestational-age
[33], indicating that haplotype status could be important
in tissue homeostasis.
Fibronectin and Fn-fs interact with chondrocytes and
other joint tissue cells through integrins by which they
can regulate cell function through a variety of intracellular
signal cascades [5,34,35]. Although the α5β1 integrin is
the major fibronectin receptor expressed by chondrocytes[7], αV is also abundantly expressed by articular chondro-
cytes; however, its biological significance in cartilage has
been less well studied. ITGAV polymorphisms are associ-
ated with a number of conditions including rheumatoid
arthritis [36], chronic hepatitis B virus infection [37], and
primary biliary cirrhosis [38]. In the current study, the
ITGAV SNP rs10174098A/G was only associated with knee
OA when both study data were combined. Thus it is not
entirely clear whether this weaker association with
OA is genuine. Further independent studies need to
be undertaken to clarify the situation.
Conclusion
The present study suggests that there is a significant
association with the FN-1 polymorphism rs940739A/T
and susceptibility to knee OA in a Chinese Han population.
Such polymorphisms may explain why some individ-
uals are at a higher risk for knee OA. Further studies
on other larger populations combined with in vitro
functional analyses are now crucial to elucidate the
effects of the polymorphism on knee OA pathogenesis
and susceptibility.
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